return equiti ttm
upgrad outperform
market perform thesi base competit enter cf market
monday march market open proteostasi pti announc
potenti amplifi treatment cystic fibrosi cf
top-lin data phase studi triplet combin corrector
fail match high bar set vertex studi enrol homozyg
patient two differ dose combin versu placebo treatment durat
day per protocol analysi ppa high dose combin mg
percent predict forc expiratori volum one second percentag
point pp exclud patient predispos rapid pulmonari declin match
exclus criteria vertex phase tripl combo studi dose combo saw
maximum mean improv pp versu baselin pp compar
placebo differ reach statist signific note triplet efficaci fall
short high bar set vertex tripl symdeko symdeko
achiev pp pp improv het/min patient respect
pp improv homozyg patient top symdeko although
proteostasi start phase ii studi triplet would includ higher
dose test longer durat aim optim respons data around year-end
see chanc match exceed vertex tripl efficaci low
lead market share price eros galapago glpg
outperform proteostasi shown subpar data
stronger price power maintain high probabl success vertex tripl
combo reach market ascrib peak sale billion
billion previous made follow chang market model
increas peak market share vertex tripl reach market unit state
eu respect chang annual
price increas unit state eu declin
respect continu model annual price declin
continu project vertex tripl combo launch first half unit
state follow first half launch eu npv model valu compani
cf franchis per share togeth net cash per share year-end
deriv fair valu vertex share note model includ
valu program cf gene therapi program outsid cf expect high
ep growth oper margin expans next year drive valu
pipelin candid start enter valuat well
biopharmaceut compani focus develop commerci therapi
cystic fibrosi compani lead asset kalydeco kalydeco lumacaftor combo registr next-
gener combin clinic develop
upgrad vertex share outperform market perform rais fair
valu estim base increas domin cf market
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
follow triplet combo data releas proteostasi underwhelm compar vertex
tripl combo result look next data differ dose tripl combo expect
releas end year per protocol analysi ppa dose combin mg
mg mg produc maximum mean absolut improv percent predict forc expiratori volum
one second percentag point pp exclud patient predispos rapid pulmonari declin match
exclus criteria vertex phase tripl combo studi dose combo saw maximum mean improv
pp versu baselin pp compar placebo differ reach statist signific note
triplet efficaci fall short high bar set vertex tripl symdeko symdeko
achiev pp pp improv het/min patient respect pp improv
homozyg patient top symdeko
sweat chlorid statist signific decreas day mm compar baselin
mm compar placebo howev also fall short mm reduct vertex tripl combo demonstr
proteostasi manag note follow day treatment tripl combo increas yet
plateau like cftr amplifi may requir longer durat therapi manifest potenc
pk/pd model suggest tripl combo mg mg mg would
optim produc better data tripl combo describ compani plan initi phase ii studi
tripl durat day anticip data around year-end phase studi expect start
given high bar set vertex tripl combo studi believ competit regimen proteostasi
low chanc meet exceed vertex tripl combo efficaci long-term safeti also issu watch
regimen like becom altern treatment option especi nonrespond believ vertex like
domin cf landscap forese futur
data vertex tripl symdeko symdeko remain strongest date await
choic regimen expect occur follow full data expect second quarter
nda file note tripl combo symdeko symdeko achiev pp
pp improv het/min patient respect pp improv homozyg patient
top symdeko data far best field pois vertex treat cf market singl
treatment vertex plan wait full data choos better regimen submit regulatori approv
global avail second quarter compani plan submit nda fda third quarter
follow europ fourth quarter
vertex plan conduct dose-rang phase ii studi monotherapi gate mutat start earli
expect incorpor phase studi like late earli phase ii
studi read satisfactori efficaci safeti data deuter version kalydeco licens
allow once-daili dose posit becom new potenti
backbon tripl combo regimen note kalydeco compon tripl combo dose twice
daili top-lin result phase ii studi evalu part tripl combin regimen het/min patient
show mean absolut improv pp pp combin tezacaftor
tezacaftor respect result similar efficaci safeti compar prior phase ii studi
compani tripl combin includ kalydeco support advanc phase test compani
origin intend start around howev fda view new chemic entiti agenc
request addit dose rang data henc phase ii monotherapi studi compani pursu phase
beyond cf vertex sever pipelin candid variou stage treatment antitrypsin defici
pain sickl cell disease/beta thalassemia focal segment glomerulosclerosi vertex enter clinic
develop decemb oral small molecul corrector antitrypsin defici life
threaten diseas high unmet treatment need affect approxim patient unit state eu
manag note small molecul corrector also develop collabor crispr therapeut
crsp market perform vertex initi phase i/ii clinic studi gene edit therapi patient
sickl cell diseas beta thalassemia track design two indic repres opportun
approxim patient unit state eu decemb vertex present posit data phase ii
studi oral dose inhibitor small fiber neuropathi third proof-of-concept studi
varieti pain condit well preclin develop inhibitor phase iib dose find
studi underway potenti support pivot develop vertex also multipl candid preclin
develop treatment focal segment glomerulosclerosi rare diseas result perman kidney damag
compani plan advanc first potenti medicin diseas clinic
upcom catalyst includ data tripl combo second quarter nda
submiss tripl regimen third quarter ema submiss tripl regimen fourth quarter
initi proof-of-concept data vertex program outsid cystic fibrosi next one two year
risk outperform rate vertex includ success proteostasiss tripl combo setback relat
clinic preclin busi develop activ
dollar thousand drugpeak salesstag ofdevelopmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuekalydeco cystic fibrosi gate marketedfebruari combo cystic homozyg marketedjuli orkambi feb combofor cystic phase year-end present valu addit gain loss fair includ cost directli relat program abovesourc compani report william blair compani estimatesexhibit pharmaceut incorporatedsum-of-part fair valu import disclosur
